L&C Bio secured a 에볼루션 바카라 사이트 for 'ultra-fine acellular dermal manufacturing technology' designed to minimize patient discomfort

[by Yu, Suin] L&C Bio, a company specializing in regenerative medicine for human tissue, announced on April 16 that it has secured a 에볼루션 바카라 사이트 for its proprietary technology of ‘ultra-fine acellular dermis manufacturing method,’ a technology designed to be injected into damaged soft tissue regions.

The 에볼루션 바카라 사이트 was granted three years and five months after the initial application in November 2021. It encompasses the manufacturing processes for ‘MegaFill Hiject’ and ‘Aesten Inject.’

The registered 에볼루션 바카라 사이트 pertains to a manufacturing technology of ultra-fine acellular dermis in a form that can be discharged (expelling liquid, gas, or powder out of a machine or device) through a micro-diameter needle. This is achieved through an ultra-low temperature pulverization process that preserves the collagen content and structural integrity of the acellular dermis. The technology is notable for its ability to reduce patient discomfort by making it possible to inject into soft tissue using a micro-needle.

To enable the injection of acellular dermis into the human body, it is essential to subject the material to a micro-processing technique to reduce its size. To minimize patient discomfort during injection, the processed material must be manufactured in a way that it can discharge even from a micro-diameter needle. However, the heat generated during the conventional micronization process can denature collagen, the primary component of acellular dermis, thereby compromising its original functional properties, including tissue reinforcement through the activation of growth factors and cells.

The newly 에볼루션 바카라 사이트ed technology is based on a three-step micronization process. The first step involves the physical crushing of the acellular dermis. In the second step, the material is frozen at an ultra-low temperature and further pulverized. The final step entails a sieve-based separation process using strong suction to obtain acellular dermis particles of uniform size. According to the company, this advanced process has improved productivity by increasing the yield of acellular dermis while reducing the overall processing time compared to conventional methods.

The micronized acellular dermis, primarily composed of collagen, plays a key role in activating cells and growth factors in the body. It is applicable to a wide range of indications, including degenerative arthritis, cervical and spinal disc disorders, and plantar fasciitis. Its therapeutic purpose lies in promoting recovery and regeneration in various tissues, such as damaged muscles, biomembranes, ligaments, and cartilage.

Currently, ‘MegaFill Hiject’ and ‘Aesten Inject,’ developed using the 에볼루션 바카라 사이트ed technology, activate cells and growth factors in the body and demonstrate excellent efficacy in the treatment of damaged tissues, including tendons, ligaments, and muscles, as well as in the regeneration of soft tissues. These products are widely used in frontline medical institutions.

With this acquisition of this 에볼루션 바카라 사이트, L&C Bio intends to accelerate its sales and marketing efforts to promote the active clinical use of its products. The company noted that the 에볼루션 바카라 사이트 will serve to protect the quality of its offerings and safeguard its proprietary, unique technology.

“Since our founding, we have evolved into one of Korea’s leading companies in the field of tissue engineering, driven by evidence-based joint research and development in close collaboration with some of the country’s top medical professionals,” stated Lee Whan Chul, CEO of L&C Bio. “Earlier this year, we received approval for ‘MegaDerm Plus’ from China’s National Medical Products Administration (NMPA), and full-scale commercialization in the Chinese market is set to begin in the second quarter. Building on this momentum, we will accelerate efforts to enhance corporate value and expand our global presence.”

L&C Bio currently operates three corporate research institutes, including L&C ES and the Global Medical Research Center, and remains dedicated to the development of innovative, next-generation products in each area of specialization. As of April 2025, the company has secured intellectual property rights through a total of 27 에볼루션 바카라 사이트s (25 in Korea, 2 in the United States). Additionally, L&C Bio is actively pursuing additional intellectual property rights, with 50 에볼루션 바카라 사이트 applications currently in progress (23 in Korea, 17 under the 에볼루션 바카라 사이트 Cooperation Treaty [PCT], and 10 in the United States). The company has also published 78 SCI-indexed papers in collaboration with leading medical professionals, and this number is expected to exceed 100 within the year.